Prognostic value of hemodynamic vs big endothelin measurements during long-term IV therapy in advanced heart failure patients

Chest

Volumn 117, Issue 6, 2000, Pages 1713-1719

  Frey, Bernhard ^b   Pacher, Richard ^c   Locker, Gottfried ^c   Bojic, Anda ^a   Hartter, Engelbert ^c   Woloszczuk, Wolfgang ^a   Stanek, Brigitte ^c  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Abteilung für Kardiologie ^*

Author keywords

Big endothelin; Dobutamine; Heart failure; Heart transplantation; Prostaglandin E1

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIG ENDOTHELIN 1; BIG ENDOTHELIN 2; BIG ENDOTHELIN 3; CAPTOPRIL; CARVEDILOL; DIGOXIN; DOBUTAMINE; ENALAPRIL; FUROSEMIDE; PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART INDEX; HEART TRANSPLANTATION; HEMODYNAMIC MONITORING; HUMAN; LONG TERM CARE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE;

EID: 0034047124     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.6.1713     Document Type: Article

References (26)

1. 1 Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis 1998; 41:207-224
2. 2 Pacher R, Stanek B. Ambulatory vasodilatory therapy in heart failure: systematic review of the literature and personal observational experience. Eur J Heart Failure 1999; 1:263-268
3. 3 Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinant of prognosis in heart failure. Circulation 1993; 87(suppl): V15-V16
4. 4 Pacher R, Bergler-Klein J, Globits S, et al. Plasma big endothekin-1 concentrations in congestive heart failure compared to systemic hypertension. Am J Cardiol 1993; 71:1293-1299
5. 5 Pacher R, Stanek B, Hülsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996; 27:633-641
6. 6 Stanek B, Frey B, Hülsmann M, et al. Validation of big endothelin plasma levels compared with established neurohumoral markers in patients with severe chronic heart failure. Transplant Proc 1997; 29:595-596
7. 7 Hülsmann M, Stanek B, Frey B, et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998; 32:1695-1700
8. 8 Stanek B, Sturm B, Frey B, et al. Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. J Heart Lung Transplant 1999; 18:358-366
9. 9 Califf RM, Adams KF, McKenna W, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Trial (FIRST). Am Heart J 1997; 134:44-54
10. 10 Krum H, Goldsmith R, Wilshire-Clement M, et al. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995; 75:1282-1283
11. 11 Kubo SH, Rector TS, Bank AJ, et al. Endothelium dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84:1589-1596
12. 12 Noll G, Wenzel RR, Lüscher TF. Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease. Mol Cell Biochem 1996; 157:259-267
13. 13 Dzau VJ. The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. Curr Opin Nephrol Hypertens 1993; 2:27-32
14. 14 Gerdes AM, Capasso JM. Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol 1995; 27:849-856
15. 15 Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384:353-355
16. 16 Sütsch G, Bertel O, Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther 1997; 10:717-725
17. 17 Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85:504-509
18. 18 Tsutamato T, Wada A, Maeda Y, et al. Relation between endothelin spillover in the lungs and pulmonary resistance in patients with chronic heart failure. J Am Coll Cardiol 1994; 23:1427-1433
19. 19 Drexler H, Hayoz D, Münzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69:1596-1601
20. 20 Warner TD, Klemm P. What turns on the endothelins? Inflamm Res 1996; 45:51-53
21. 21 Krum H, Itescu S. Spontaneous endothelin production by circulating mononuclear cells from patients with chronic heart failure but not from normal subjects. Clin Exp Pharmacol Physiol 1994; 21:311-313
22. 22 Webb DJ. Evidence for endothelin mediated vasoconstriction in severe chronic heart failure: endothelin antagonism in heart failure. Circulation 1995; 92:3372
23. 23 Hedqvist P. Basic mechanism of prostaglandin action on autonomie neurotransmission. Annu Rev Pharmacol Toxicol 1977; 17:259-265
24. 24 Yamamoto K, Burnett JC, JougasaM M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28:988-994
25. 25 Arakawa N, Nakamura M, Aoki H, et al. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 1996; 27:1656-1661
26. 26 Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97:1921-1929